glp-1 next generation Beyond GLP-1: Review of Next-Generation Obesity Therapeutics The Race for the Next

Efficacy of semaglutide in a subcutaneous and an oral formulation

Not on purpose

Based upon self-reported data from approximately 12,000 customers subscribed to a comprehensive Hims & Hers weight loss offering, customers report having lost, on average, 10.2 pounds while on compounded GLP-1 injections and 6.3 pounds while on non-GLP-1 compounded oral medication kits, along with a reduced calorie diet and exercise, between their initial weight at consultation and their first check-in approximately 4 weeks later

Recent data suggests the risk may be greater than previously understood, particularly for people taking Wegovy, the higher-dose version of semaglutide used for weight loss